CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Sutent for pancreatic neuroendocrine tumours – Details

Project Number PC0004-000
Brand Name Sutent
Generic Name Sunitinib malate
Strength 12.5mg, 25mg, 50mg
Tumour Type Gastrointestinal
Indication Pancreatic neuroendocrine tumours
Funding Request Patients with unresectable locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumours, whose disease is progressive
Review Status Complete
Pre Noc Submission No
NOC Date June 30, 2011
Manufacturer Pfizer Canada Inc.
Sponsor Pfizer Canada Inc.
Submission Date November 7, 2011
Submission Deemed Complete November 14, 2011
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ November 22, 2011
Check-point meeting January 9, 2012
pERC Meeting February 16, 2012
Initial Recommendation Issued March 2, 2012
Feedback Deadline ‡ March 16, 2012
pERC Reconsideration Meeting April 19, 2012
Final Recommendation Issued May 3, 2012
Notification to Implement Issued May 18, 2012
Therapeutic Area Pancreatic Neuroendocrine Tumour
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.